DOCSLIB.ORG

Mouse Ddx25 Conditional Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

https://www.alphaknockout.com Mouse Ddx25 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Ddx25 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Ddx25 gene (NCBI Reference Sequence: NM_013932 ; Ensembl: ENSMUSG00000032101 ) is located on Mouse chromosome 9. 12 exons are identified, with the ATG start codon in exon 1 and the TGA stop codon in exon 12 (Transcript: ENSMUST00000034612). Exon 5~6 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Ddx25 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP24-387H14 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Homozygous null mice display male infertility, arrest of spermatogenesis at step 8, abnormal Leydig cells, and increased germ cell apoptosis in males. Exon 5 starts from about 21.69% of the coding region. The knockout of Exon 5~6 will result in frameshift of the gene. The size of intron 4 for 5'-loxP site insertion: 2156 bp, and the size of intron 6 for 3'-loxP site insertion: 1355 bp. The size of effective cKO region: ~803 bp. The cKO region does not have any other known gene. Page 1 of 7 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 4 5 6 7 12 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Ddx25 Homology arm cKO region loxP site Page 2 of 7 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. No significant tandem repeat is found in the dot plot matrix. So this region is suitable for PCR screening or sequencing analysis. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(7303bp) | A(26.58% 1941) | C(22.35% 1632) | T(28.71% 2097) | G(22.36% 1633) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Page 3 of 7 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr9 - 35554860 35557859 3000 browser details YourSeq 76 2105 2208 3000 87.4% chr14 + 7833884 7833983 100 browser details YourSeq 73 2108 2208 3000 87.0% chr13 + 59511414 59511510 97 browser details YourSeq 72 2071 2209 3000 85.4% chr11 - 50781322 50781457 136 browser details YourSeq 68 2108 2208 3000 84.4% chr2 - 171025520 171025616 97 browser details YourSeq 68 2108 2208 3000 85.2% chr11 + 104511674 104511770 97 browser details YourSeq 67 2108 2205 3000 85.0% chr2 - 94041054 94041147 94 browser details YourSeq 67 2105 2208 3000 86.9% chr19 - 53995597 53995696 100 browser details YourSeq 67 2108 2208 3000 86.9% chr14 - 67694806 67694901 96 browser details YourSeq 66 2146 2240 3000 84.0% chr14 - 100469661 100469747 87 browser details YourSeq 65 2105 2208 3000 86.5% chr12 - 55917942 55918041 100 browser details YourSeq 65 2106 2208 3000 84.7% chr11 - 82906067 82906165 99 browser details YourSeq 65 2108 2204 3000 84.2% chr1 - 45930625 45930717 93 browser details YourSeq 64 2108 2208 3000 86.4% chr2 - 85039227 85039323 97 browser details YourSeq 64 2108 2208 3000 86.4% chr3 + 84648099 84648195 97 browser details YourSeq 64 2108 2208 3000 86.4% chr16 + 35331276 35331372 97 browser details YourSeq 63 2108 2208 3000 82.4% chr10 - 62932374 62932471 98 browser details YourSeq 62 2108 2208 3000 85.0% chr15 - 73208176 73208272 97 browser details YourSeq 62 2108 2208 3000 86.2% chr17 + 88259596 88259692 97 browser details YourSeq 61 2109 2208 3000 84.8% chr2 - 155037752 155037847 96 Note: The 3000 bp section upstream of Exon 5 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr9 - 35551057 35554056 3000 browser details YourSeq 151 2304 2476 3000 94.3% chr19 + 47228039 47228214 176 browser details YourSeq 150 2299 2473 3000 93.7% chr2 - 20285881 20286056 176 browser details YourSeq 149 2320 2478 3000 96.9% chr1 - 63500980 63501138 159 browser details YourSeq 146 2325 2476 3000 98.1% chr6 - 65151999 65152150 152 browser details YourSeq 145 2316 2476 3000 93.8% chr7 + 72339850 72340009 160 browser details YourSeq 144 2317 2476 3000 94.4% chr4 - 149776528 149776686 159 browser details YourSeq 144 2317 2476 3000 94.3% chr15 + 59101626 59101783 158 browser details YourSeq 143 2042 2458 3000 86.0% chr4 - 17385190 17385589 400 browser details YourSeq 143 2321 2476 3000 94.2% chr3 - 145355996 145356149 154 browser details YourSeq 143 2316 2476 3000 95.0% chr15 - 36940630 36940792 163 browser details YourSeq 142 2320 2476 3000 92.9% chrX - 22087934 22088087 154 browser details YourSeq 142 2315 2494 3000 92.3% chr11 + 75527803 75527982 180 browser details YourSeq 142 2317 2476 3000 95.0% chr11 + 12400913 12401084 172 browser details YourSeq 141 2311 2473 3000 93.8% chr2 - 107593537 107593954 418 browser details YourSeq 141 2316 2476 3000 96.1% chr5 + 122411321 122411485 165 browser details YourSeq 141 2317 2476 3000 92.5% chr12 + 111873216 111873373 158 browser details YourSeq 141 2320 2476 3000 93.0% chr10 + 50440966 50441120 155 browser details YourSeq 140 2316 2476 3000 92.4% chr4 - 11017858 11018016 159 browser details YourSeq 140 2316 2476 3000 93.8% chr10 + 30428175 30428343 169 Note: The 3000 bp section downstream of Exon 6 is BLAT searched against the genome. No significant similarity is found. Page 4 of 7 https://www.alphaknockout.com Gene and protein information: Ddx25 DEAD (Asp-Glu-Ala-Asp) box polypeptide 25 [ Mus musculus (house mouse) ] Gene ID: 30959, updated on 10-Oct-2019 Gene summary Official Symbol Ddx25 provided by MGI Official Full Name DEAD (Asp-Glu-Ala-Asp) box polypeptide 25 provided by MGI Primary source MGI:MGI:1353582 See related Ensembl:ENSMUSG00000032101 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as GRTH; AW047046 Expression Biased expression in testis adult (RPKM 116.1), CNS E18 (RPKM 19.3) and 5 other tissues See more Orthologs human all Genomic context Location: 9; 9 A4 See Ddx25 in Genome Data Viewer Exon count: 12 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 9 NC_000075.6 (35541848..35558470, complement) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 9 NC_000075.5 (35349433..35366055, complement) Chromosome 9 - NC_000075.6 Page 5 of 7 https://www.alphaknockout.com Transcript information: This gene has 1 transcript Gene: Ddx25 ENSMUSG00000032101 Description DEAD (Asp-Glu-Ala-Asp) box polypeptide 25 [Source:MGI Symbol;Acc:MGI:1353582] Gene Synonyms GRTH Location Chromosome 9: 35,536,647-35,558,528 reverse strand. GRCm38:CM001002.2 About this gene This gene has 1 transcript (splice variant), 139 orthologues, 39 paralogues, is a member of 1 Ensembl protein family and is associated with 6 phenotypes. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Ddx25-201 ENSMUST00000034612.6 6934 484aa ENSMUSP00000034612.4 Protein coding CCDS52753 Q9QY15 TSL:1 GENCODE basic APPRIS P1 41.88 kb Forward strand 35.53Mb 35.54Mb 35.55Mb 35.56Mb Genes Pus3-203 >retained intron (Comprehensive set... Pus3-201 >protein coding Pus3-202 >protein coding Contigs < AC118232.10 Genes (Comprehensive set... < Ddx25-201protein coding < Hyls1-201protein coding < Hyls1-202retained intron Regulatory Build 35.53Mb 35.54Mb 35.55Mb 35.56Mb Reverse strand 41.88 kb Regulation Legend CTCF Enhancer Open Chromatin Promoter Promoter Flank Transcription Factor Binding Site Gene Legend Protein Coding merged Ensembl/Havana Ensembl protein coding Non-Protein Coding processed transcript Page 6 of 7 https://www.alphaknockout.com Transcript: ENSMUST00000034612 < Ddx25-201protein coding Reverse strand 21.88 kb ENSMUSP00000034... Low complexity (Seg) Superfamily P-loop containing nucleoside triphosphate hydrolase SMART Helicase superfamily 1/2, ATP-binding domain Helicase, C-terminal Pfam DEAD/DEAH box helicase domain Helicase, C-terminal PROSITE profiles RNA helicase, DEAD-box type, Q motif Helicase, C-terminal Helicase superfamily 1/2, ATP-binding domain PANTHER PTHR24031 PTHR24031:SF331 Gene3D 3.40.50.300 CDD cd18048 cd18787 All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend inframe insertion synonymous variant Scale bar 0 60 120 180 240 300 360 420 484 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC. Page 7 of 7.
Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Analysis of the Indacaterol-Regulated Transcriptome in Human Airway

    Analysis of the Indacaterol-Regulated Transcriptome in Human Airway

    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/04/13/jpet.118.249292.DC1 1521-0103/366/1/220–236$35.00 https://doi.org/10.1124/jpet.118.249292 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:220–236, July 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the s Adverse and Therapeutic Effects of b2-Adrenoceptor Agonists Dong Yan, Omar Hamed, Taruna Joshi,1 Mahmoud M. Mostafa, Kyla C. Jamieson, Radhika Joshi, Robert Newton, and Mark A. Giembycz Departments of Physiology and Pharmacology (D.Y., O.H., T.J., K.C.J., R.J., M.A.G.) and Cell Biology and Anatomy (M.M.M., R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada Received March 22, 2018; accepted April 11, 2018 Downloaded from ABSTRACT The contribution of gene expression changes to the adverse and activity, and positive regulation of neutrophil chemotaxis. The therapeutic effects of b2-adrenoceptor agonists in asthma was general enriched GO term extracellular space was also associ- investigated using human airway epithelial cells as a therapeu- ated with indacaterol-induced genes, and many of those, in- tically relevant target. Operational model-fitting established that cluding CRISPLD2, DMBT1, GAS1, and SOCS3, have putative jpet.aspetjournals.org the long-acting b2-adrenoceptor agonists (LABA) indacaterol, anti-inflammatory, antibacterial, and/or antiviral activity. Numer- salmeterol, formoterol, and picumeterol were full agonists on ous indacaterol-regulated genes were also induced or repressed BEAS-2B cells transfected with a cAMP-response element in BEAS-2B cells and human primary bronchial epithelial cells by reporter but differed in efficacy (indacaterol $ formoterol .
  • Chloride Channels Regulate Differentiation and Barrier Functions

    Chloride Channels Regulate Differentiation and Barrier Functions

    RESEARCH ARTICLE Chloride channels regulate differentiation and barrier functions of the mammalian airway Mu He1†*, Bing Wu2†, Wenlei Ye1, Daniel D Le2, Adriane W Sinclair3,4, Valeria Padovano5, Yuzhang Chen6, Ke-Xin Li1, Rene Sit2, Michelle Tan2, Michael J Caplan5, Norma Neff2, Yuh Nung Jan1,7,8, Spyros Darmanis2*, Lily Yeh Jan1,7,8* 1Department of Physiology, University of California, San Francisco, San Francisco, United States; 2Chan Zuckerberg Biohub, San Francisco, United States; 3Department of Urology, University of California, San Francisco, San Francisco, United States; 4Division of Pediatric Urology, University of California, San Francisco, Benioff Children’s Hospital, San Francisco, United States; 5Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Heaven, United States; 6Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, United States; 7Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States; 8Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, United States *For correspondence: Abstract The conducting airway forms a protective mucosal barrier and is the primary target of [email protected] (MH); [email protected] airway disorders. The molecular events required for the formation and function of the airway (SD); mucosal barrier, as well as the mechanisms by which barrier dysfunction leads to early onset airway [email protected] (LYJ) diseases,
  • Systematic Analysis of Palatal Transcriptome to Identify Cleft Palate Genes Within Tgfβ3-Knockout Mice Alleles: RNA-Seq Analysis of Tgfβ3 Mice Ozturk Et Al

    Systematic Analysis of Palatal Transcriptome to Identify Cleft Palate Genes Within Tgfβ3-Knockout Mice Alleles: RNA-Seq Analysis of Tgfβ3 Mice Ozturk Et Al

    Systematic analysis of palatal transcriptome to identify cleft palate genes within TGFβ3-knockout mice alleles: RNA-Seq analysis of TGFβ3 Mice Ozturk et al. Ozturk et al. BMC Genomics 2013, 14:113 http://www.biomedcentral.com/1471-2164/14/113 Ozturk et al. BMC Genomics 2013, 14:113 http://www.biomedcentral.com/1471-2164/14/113 RESEARCH ARTICLE Open Access Systematic analysis of palatal transcriptome to identify cleft palate genes within TGFβ3-knockout mice alleles: RNA-Seq analysis of TGFβ3 Mice Ferhat Ozturk1,4, You Li2, Xiujuan Zhu1, Chittibabu Guda2,3 and Ali Nawshad1* Abstract Background: In humans, cleft palate (CP) accounts for one of the largest number of birth defects with a complex genetic and environmental etiology. TGFβ3 has been established as an important regulator of palatal fusion in mice and it has been shown that TGFβ3-null mice exhibit CP without any other major deformities. However, the genes that regulate cellular decisions and molecular mechanisms maintained by the TGFβ3 pathway throughout palatogenesis are predominantly unexplored. Our objective in this study was to analyze global transcriptome changes within the palate during different gestational ages within TGFβ3 knockout mice to identify TGFβ3-associated genes previously unknown to be associated with the development of cleft palate. We used deep sequencing technology, RNA-Seq, to analyze the transcriptome of TGFβ3 knockout mice at crucial stages of palatogenesis, including palatal growth (E14.5), adhesion (E15.5), and fusion (E16.5). Results: The overall transcriptome analysis of TGFβ3 wildtype mice (C57BL/6) reveals that almost 6000 genes were upregulated during the transition from E14.5 to E15.5 and more than 2000 were downregulated from E15.5 to E16.5.
  • Based on Network Pharmacology and RNA Sequencing Techniques to Explore the Molecular Mechanism of Huatan Jiangzhuo Decoction for Treating Hyperlipidemia

    Based on Network Pharmacology and RNA Sequencing Techniques to Explore the Molecular Mechanism of Huatan Jiangzhuo Decoction for Treating Hyperlipidemia

    Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2021, Article ID 9863714, 16 pages https://doi.org/10.1155/2021/9863714 Research Article Based on Network Pharmacology and RNA Sequencing Techniques to Explore the Molecular Mechanism of Huatan Jiangzhuo Decoction for Treating Hyperlipidemia XiaowenZhou ,1 ZhenqianYan ,1 YaxinWang ,1 QiRen ,1 XiaoqiLiu ,2 GeFang ,3 Bin Wang ,4 and Xiantao Li 1 1Laboratory of TCM Syndrome Essence and Objectification, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China 2Guangzhou Sagene Tech Co., Ltd., Guangzhou 510006, China 3College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China 4Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518000, China Correspondence should be addressed to Xiantao Li; [email protected] Received 22 May 2020; Revised 12 March 2021; Accepted 18 March 2021; Published 12 April 2021 Academic Editor: Jianbo Wan Copyright © 2021 Xiaowen Zhou et al. +is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Hyperlipidemia, due to the practice of unhealthy lifestyles of modern people, has been a disturbance to a large portion of population worldwide. Recently, several scholars have turned their attention to Chinese medicine (CM) to seek out a lipid-lowering approach with high efficiency and low toxicity. +is study aimed to explore the mechanism of Huatan Jiangzhuo decoction (HTJZD, a prescription of CM) in the treatment of hyperlipidemia and to determine the major regulation pathways and potential key targets involved in the treatment process.
  • Whole-Exome Sequencing Identifies Causative Mutations in Families

    Whole-Exome Sequencing Identifies Causative Mutations in Families

    BASIC RESEARCH www.jasn.org Whole-Exome Sequencing Identifies Causative Mutations in Families with Congenital Anomalies of the Kidney and Urinary Tract Amelie T. van der Ven,1 Dervla M. Connaughton,1 Hadas Ityel,1 Nina Mann,1 Makiko Nakayama,1 Jing Chen,1 Asaf Vivante,1 Daw-yang Hwang,1 Julian Schulz,1 Daniela A. Braun,1 Johanna Magdalena Schmidt,1 David Schapiro,1 Ronen Schneider,1 Jillian K. Warejko,1 Ankana Daga,1 Amar J. Majmundar,1 Weizhen Tan,1 Tilman Jobst-Schwan,1 Tobias Hermle,1 Eugen Widmeier,1 Shazia Ashraf,1 Ali Amar,1 Charlotte A. Hoogstraaten,1 Hannah Hugo,1 Thomas M. Kitzler,1 Franziska Kause,1 Caroline M. Kolvenbach,1 Rufeng Dai,1 Leslie Spaneas,1 Kassaundra Amann,1 Deborah R. Stein,1 Michelle A. Baum,1 Michael J.G. Somers,1 Nancy M. Rodig,1 Michael A. Ferguson,1 Avram Z. Traum,1 Ghaleb H. Daouk,1 Radovan Bogdanovic,2 Natasa Stajic,2 Neveen A. Soliman,3,4 Jameela A. Kari,5,6 Sherif El Desoky,5,6 Hanan M. Fathy,7 Danko Milosevic,8 Muna Al-Saffar,1,9 Hazem S. Awad,10 Loai A. Eid,10 Aravind Selvin,11 Prabha Senguttuvan,12 Simone Sanna-Cherchi,13 Heidi L. Rehm,14 Daniel G. MacArthur,14,15 Monkol Lek,14,15 Kristen M. Laricchia,15 Michael W. Wilson,15 Shrikant M. Mane,16 Richard P. Lifton,16,17 Richard S. Lee,18 Stuart B. Bauer,18 Weining Lu,19 Heiko M. Reutter ,20,21 Velibor Tasic,22 Shirlee Shril,1 and Friedhelm Hildebrandt1 Due to the number of contributing authors, the affiliations are listed at the end of this article.
  • The Molecular Basis of Hydrolethalus Syndrome

    The Molecular Basis of Hydrolethalus Syndrome

    Heli Honkala The Molecular Basis of RESEARCH Hydrolethalus Syndrome 5 Heli Honkala THE MOLECULAR BASIS OF HYDROLETHALUS SYNDROME ACADEMIC DISSERTATION To be presented with the permission of the Faculty of Biosciences, University of Helsinki, for public examination in Lecture Hall 2, Biomedicum Helsinki, on April 3rd , 2009, at noon. National Public Health Institute and National Institute for Health and Welfare and Division of Genetics, Department of Biological and Environmental Sciences, Faculty of Biosciences, University of Helsinki and Helsinki Biomedical Graduate School Helsinki, Finland 2009 Helsinki University Biomedical Dissertations No. 118 ISSN 1457-8433 © National Institute for Health and Welfare ISBN 978- 952-245-034-0 (painettu) ISBN 978- 952-245-035-7 (verkkojulkaisu) ISSN 1798-0054 (painettu) ISSN 1798-0062 (verkkojulkaisu) Kannen kuva - cover graphic: Heli Honkala Yliopistopaino Helsinki 2009 Supervised by Docent Marjo Kestilä Department of Chronic Disease Prevention Public Health Genomics National Institute for Health and Welfare Helsinki, Finland Reviewed by Professor Anna-Elina Lehesjoki Folkhälsan Institute of Genetics and Neuroscience Center, University of Helsinki Helsinki, Finland Professor Raili Myllylä Department of Biochemistry University of Oulu Oulu, Finland Opponent Docent Sirpa Kivirikko HUSLAB Laboratory of Molecular Genetics Helsinki University Central Hospital Helsinki, Finland Custos Professor Katarina Pelin Department of Biological and Environmental Sciences Division of Genetics University of Helsinki Helsinki, Finland “Don't fear change – embrace it.” Anthony J. D'Angelo To my family Heli Honkala, The Molecular Basis of Hydrolethalus Syndrome Publications of the National Institute for Health and Welfare, 5|2009, 86 Pages ISBN 978- 952-245-034-0 (print); 978- 952-245-035-7 (pdf-version) ISSN 1798-0054 (print); 1798-0062 (pdf-version) http://www.thl.fi ABSTRACT Hydrolethalus syndrome (HLS) is a severe fetal malformation syndrome that is inherited by an autosomal recessive manner.
  • Supplemental Data.Pdf

    Supplemental Data.Pdf

    Supplementary material -Table of content Supplementary Figures (Fig 1- Fig 6) Supplementary Tables (1-13) Lists of genes belonging to distinct biological processes identified by GREAT analyses to be significantly enriched with UBTF1/2-bound genes Supplementary Table 14 List of the common UBTF1/2 bound genes within +/- 2kb of their TSSs in NIH3T3 and HMECs. Supplementary Table 15 List of gene identified by microarray expression analysis to be differentially regulated following UBTF1/2 knockdown by siRNA Supplementary Table 16 List of UBTF1/2 binding regions overlapping with histone genes in NIH3T3 cells Supplementary Table 17 List of UBTF1/2 binding regions overlapping with histone genes in HMEC Supplementary Table 18 Sequences of short interfering RNA oligonucleotides Supplementary Table 19 qPCR primer sequences for qChIP experiments Supplementary Table 20 qPCR primer sequences for reverse transcription-qPCR Supplementary Table 21 Sequences of primers used in CHART-PCR Supplementary Methods Supplementary Fig 1. (A) ChIP-seq analysis of UBTF1/2 and Pol I (POLR1A) binding across mouse rDNA. UBTF1/2 is enriched at the enhancer and promoter regions and along the entire transcribed portions of rDNA with little if any enrichment in the intergenic spacer (IGS), which separates the rDNA repeats. This enrichment coincides with the distribution of the largest subunit of Pol I (POLR1A) across the rDNA. All sequencing reads were mapped to the published complete sequence of the mouse rDNA repeat (Gene bank accession number: BK000964). The graph represents the frequency of ribosomal sequences enriched in UBTF1/2 and Pol I-ChIPed DNA expressed as fold change over those of input genomic DNA.
  • Discovery, Diagnosis, and Etiology of Craniofacial Ciliopathies

    Discovery, Diagnosis, and Etiology of Craniofacial Ciliopathies

    Downloaded from http://cshperspectives.cshlp.org/ on September 30, 2021 - Published by Cold Spring Harbor Laboratory Press Discovery, Diagnosis, and Etiology of Craniofacial Ciliopathies Elizabeth N. Schock and Samantha A. Brugmann Division of Plastic Surgery, Department of Surgery, and Division of Developmental Biology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio 45229 Correspondence: [email protected] Seventy-five percent of congenital disorders present with some form of craniofacial malfor- mation. The frequency and severity of these malformations makes understanding the etio- logical basis crucial for diagnosis and treatment. A significant link between craniofacial malformations and primary cilia arose several years ago with the determination that 30% of ciliopathies could be primarily defined by their craniofacial phenotype. The link between the cilium and the face has proven significant, as several new “craniofacial cili- opathies” have recently been diagnosed. Herein, we reevaluate public disease databases, report several new craniofacial ciliopathies, and propose several “predicted” craniofacial ciliopathies. Furthermore, we discuss why the craniofacial complex is so sensitive to cilio- pathic dysfunction, addressing tissue-specific functions of the cilium as well as its role in signal transduction relevant to craniofacial development. As a whole, these analyses suggest a characteristic facial phenotype associated with craniofacial ciliopathies that can perhaps be used for rapid
  • THE IMPORTANT ROLE of GENETIC SCREENING Making the Best Decisions for You and Your Family

    THE IMPORTANT ROLE of GENETIC SCREENING Making the Best Decisions for You and Your Family

    THE IMPORTANT ROLE OF GENETIC SCREENING Making the best decisions for you and your family A VARIETY OF SCREENING METHODS ARE USED TO DETERMINE RISK DURING PREGNANCY Noninvasive prenatal screening Chromosome conditions Carrier screening Inherited conditions Serum screening Ultrasound Hormone and protein levels Anatomical abnormalities associated with birth defects MORE INFO Screening overview Genetic screening Noninvasive prenatal screening Carrier screening Complementary Screens During Pregnancy Screening vs. Diagnostic Tests • Several different types of screening tests are offered during • Screening tests are different than diagnostic tests pregnancy • Screening tests do not give definitive answers. Instead, they • Each is performed with the goal of assessing for risks and provide information about whether there is an increased complications in the pregnancy chance of a problem being present • Some routine screening tests done during pregnancy • Diagnostic tests, such as chorionic villus sampling (CVS) or include: carrier screening, noninvasive prenatal screening amniocentesis, are available to provide definitive information using cell-free DNA, ultrasound and maternal serum screening • Screening tests are done at different points during pregnancy and for different purposes Carrier screening and noninvasive prenatal screening, two genetic screens done early PRENATAL SCREENING on, can inform the care of your pregnancy and baby. Noninvasive prenatal screening can help avoid the need for invasive IN EARLY PREGNANCY diagnostic tests (indicated
  • Novel Mutations for Nonsyndromic Cleft Lip and Palate in Two Consanguineous Palestinian Families

    Novel Mutations for Nonsyndromic Cleft Lip and Palate in Two Consanguineous Palestinian Families

    Joint Biotechnology Master Program Palestine Polytechnic University Bethlehem University Deanship of Graduate Studies and Faculty of Science Scientific Research Novel Mutations for Nonsyndromic Cleft Lip and Palate in Two Consanguineous Palestinian Families By Rawan Bilal Abu Geith In Partial Fulfillment of the Requirements for the Degree Master of Science December, 2015 Novel Mutations for Nonsyndromic Cleft Lip and Palate in Two Consanguineous Palestinian Families ABSTRACT Cleft lip and\or palate (CL/ CP) is the most common congenital malformation that affects the upper lip and the roof of the mouth. It is one of the most frequent congenital anomalies, affecting 1 in every 500 to 1000 births worldwide. In the Middle East, the incidence has variably been reported as 0.3 to 2.19 per 1000 lives. Higher incidence can be attributed to the high percentage of consanguineous marriages and low socioeconomic status (SES). Individuals with CL/ CP may face many problems in breathing, feeding, hearing, language and social integration. They need to undergo many reparative surgeries as well as other non-surgical therapies. CL/ CP may manifest in different forms including: cleft lip, cleft palate only (CPO) and cleft lip with palate (CLP) according to the anatomical structure. The etiology is multifactorial, multiple genes and environmental factors play a central role in the generation of the CL/ CP phenotype. In this study, next generation exome sequencing was performed to identify the mutations for three consanguineous Palestinian families collected from Ramallah and Hebron. Genotype to phenotype segregation within the families was validated by Sanger sequencing method. Carrier frequency within the healthy population was also determined in at least 200 healthy individuals.
  • Table S1. 103 Ferroptosis-Related Genes Retrieved from the Genecards

    Table S1. 103 Ferroptosis-Related Genes Retrieved from the Genecards

    Table S1. 103 ferroptosis-related genes retrieved from the GeneCards. Gene Symbol Description Category GPX4 Glutathione Peroxidase 4 Protein Coding AIFM2 Apoptosis Inducing Factor Mitochondria Associated 2 Protein Coding TP53 Tumor Protein P53 Protein Coding ACSL4 Acyl-CoA Synthetase Long Chain Family Member 4 Protein Coding SLC7A11 Solute Carrier Family 7 Member 11 Protein Coding VDAC2 Voltage Dependent Anion Channel 2 Protein Coding VDAC3 Voltage Dependent Anion Channel 3 Protein Coding ATG5 Autophagy Related 5 Protein Coding ATG7 Autophagy Related 7 Protein Coding NCOA4 Nuclear Receptor Coactivator 4 Protein Coding HMOX1 Heme Oxygenase 1 Protein Coding SLC3A2 Solute Carrier Family 3 Member 2 Protein Coding ALOX15 Arachidonate 15-Lipoxygenase Protein Coding BECN1 Beclin 1 Protein Coding PRKAA1 Protein Kinase AMP-Activated Catalytic Subunit Alpha 1 Protein Coding SAT1 Spermidine/Spermine N1-Acetyltransferase 1 Protein Coding NF2 Neurofibromin 2 Protein Coding YAP1 Yes1 Associated Transcriptional Regulator Protein Coding FTH1 Ferritin Heavy Chain 1 Protein Coding TF Transferrin Protein Coding TFRC Transferrin Receptor Protein Coding FTL Ferritin Light Chain Protein Coding CYBB Cytochrome B-245 Beta Chain Protein Coding GSS Glutathione Synthetase Protein Coding CP Ceruloplasmin Protein Coding PRNP Prion Protein Protein Coding SLC11A2 Solute Carrier Family 11 Member 2 Protein Coding SLC40A1 Solute Carrier Family 40 Member 1 Protein Coding STEAP3 STEAP3 Metalloreductase Protein Coding ACSL1 Acyl-CoA Synthetase Long Chain Family Member 1 Protein